Sector Expert: Rahul Jasuja

Noble Financial

Image: Rahul Jasuja

Dr. Rahul Jasuja brings more than 18 years experience in the biotechnology field, which has encompassed corporate business development, sellside equity research and academia. After obtaining his bachelor's degree in microbiology from the University of Bombay and his master's degree in microbiology from the University of Montana, he earned his doctorate in immunology from Tufts University School of Medicine in Boston. Since graduation he has held progressively senior positions with Techvest Equity Research, Rodman & Renshaw, MDB Capital Group and Idera Pharmaceuticals as vice president of corporate development. Through the years, Dr. Jasuja has participated in investor and business panels, authored and coauthored several biotechnology business white papers, and successfully built institutional life sciences franchises through a long-term, deeply technical research-and-analysis approach with both educated life sciences investors.



Recent Interviews

Special Report: Highlights from BioX (10/10/12)

The first BioX Life Sciences Exposition, hosted in late September by Noble Financial Capital Markets, included a slate of seminars that explored innovation in the biotech industry, including the fields of regenerative medicine, targeted oncology and immunotherapy. Rahul Jasuja, managing director of biotechnology research with Noble Financial, moderated the targeted oncology and immunotherapy panels, and provided these exclusive summaries to The Life Sciences Report.

Biotech 'Diamonds-in-the-Rough' Promise Huge Potential Returns: Rahul Jasuja (7/19/12)

Rahul Jasuja, managing director and senior biotechnology analyst with Noble Financial Capital Markets, doesn't shy away from the smallest micro-cap companies. He relishes the potential upside in finding undervalued drug developers with technology platforms that are, frankly, difficult for most investors to understand. The micro-cap companies he covers must demonstrate scientific rigor and have management capable of executing corporate and clinical goals. In this exclusive interview with The Life Sciences Report, Jasuja shares some of his favorite names, which he believes can return major multiples back to investors.

Recent Quotes

"SYN has an experienced management team; we urge investors to pay attention."

— Rahul Jasuja, Noble Financial (10/17/13)
more >

"GALE's Abstral for breakthrough cancer pain may have competitive advantages over other fentanyl-based products."

— Rahul Jasuja, Noble Financial (5/13/13)
more >

"We rate GALE a Buy."

— Rahul Jasuja, Noble Financial (3/21/13)
more >

"GALE has a favorable risk/reward ratio."

— Rahul Jasuja, Noble Financial (1/28/13)
more >

"ONCS' electrochemotherapy program is of strategic value."

— Rahul Jasuja, Noble Financial (7/24/12)
more >

"If ONCS succeeds in phase 2 for either one of its oncology studies, the stock could react nicely."

The Life Sciences Report Interview with Rahul Jasuja (7/19/12)
more >

"ONCS has experienced management that understands the space."

— Rahul Jasuja, Noble Financial (4/30/12)
more >

"We are initiating coverage of ONCS with a Buy rating."

— Rahul Jasuja, Noble Financial (3/14/12)
more >



Due to permission requirements, not all quotes are shown.